Novartis Pumps $15M Into Israeli Stem Cell Research Firm

The Swiss drug maker Novartis will invest an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said.

Novartis last year invested $35 million in the company for a 15 percent stake, the Tachles Jewish weekly of Switzerland reported this week. The deal could reach $600 million if Novartis exercises a buyout option that expires in 2016.

The $15 million investment will be used to advance Gamida Cell’s clinical programs, including the development of an experimental treatment for patients with high risk hematological malignancies, or blood cancers such as leukemia and lymphoma and sickle cell disease.

Gamida plans to initiate a Phase III clinical trial with NiCord in mid-2016, according to Reuters.

Novartis will not have rights or options to Gamida Cell products or technology under the terms of the agreement.

Other Gamida shareholders include Israeli firms that have been the subjects of politically motivated divestment by European business, including Elbit Imaging and Teva Pharmaceutical Industries.

Author

Your Comments

The Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. All readers can browse the comments, and all Forward subscribers can add to the conversation. In the interest of maintaining a civil forum, The Forward requires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not and will be deleted. Egregious commenters or repeat offenders will be banned from commenting. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and the Forward reserves the right to remove comments for any reason.

Recommend this article

Novartis Pumps $15M Into Israeli Stem Cell Research Firm

Thank you!

This article has been sent!

Close